

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
04 APR 12 PM 4:47

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name
King & Spalding LLP

2. Address Check if different than previously reported
1730 Pennsylvania Avenue, N.W.

3. Principal Place of Business (if different from line 2)
City: Washington State/Zip (or Country): D.C. 20006

4. Contact Name Telephone
Theodore M. Hester 202-626-2901

5. Senate ID#
21632-618

7. Client Name Self
Purdue Pharma L.P.

6. House ID#
30750051

TYPE OF REPORT 8. Year 2003 Midyear (January 1 - June 30) OR Year End (July 1 - Decen

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Act

INCOME OR EXPENSE - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000
\$10,000 or more \$ 40,000
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client.

13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

Less than \$10,000
\$10,000 or more \$ _____
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate the accounting method. See instructions for description of method.

- Method A. Reporting amounts using LDA definition
 Method B. Reporting amounts under section 6033(b) Internal Revenue Code
 Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature _____

Printed Name and Title _____

LD-2 (REV. 6/98)

Page 1 of

Registrant Name King & Spalding LLP

Client Name Purdue Pharma L.P.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Congressional investigations of OxyContin[®]. Prescription drug abuse and liability legislation.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Theodore M. Hester	
William C. Talmadge	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

The foreign entity has an interest in the outcome of congressional investigations of OxyContin[®] and to combat prescription drug abuse.

Signature 

